[1]
|
Bettermann, K., Benesch, M., Weis, S. and Haybaeck, J. (2012) SUMOylation in Carcinogenesis. Cancer Letters, 316, 113-125.
|
[2]
|
Eifler, K. and Vertegaal, A.C.O. (2015) SUMOylation-Mediated Regulation of Cell Cycle Progression and Cancer. Trends in Biochemical Sciences, 40, 779-793. https://doi.org/10.1016/j.tibs.2015.09.006
|
[3]
|
Flotho, A. and Melchior, F. (2013) SUMOylation: A Regulatory Protein Modification in Health and Disease. Annual Review of Biochemistry, 82, 357-385. https://doi.org/10.1146/annurev-biochem-061909-093311
|
[4]
|
Rabellino, A., Andreani, C. and Scaglioni, P.P. (2017) The Role of PIAS SUMO E3-Ligases in Cancer. Cancer Research, 77, 1542-1547. https://doi.org/10.1158/0008-5472.CAN-16-2958
|
[5]
|
Seeler, J.S. and Dejean, A. (2017) SUMO and the Ro-bustness of Cancer. Nature Reviews Cancer, 17, 184-197.
https://doi.org/10.1038/nrc.2016.143
|
[6]
|
Wang, Y. and Dasso, M. (2009) SUMOylation and deSUMOylation at a Glance. Journal of Cell Science, 122, 4249-1252.
https://doi.org/10.1242/jcs.050542
|
[7]
|
Mahajan, R., Delphin, C., Guan, T., Gerace, L. and Melchior, F. (1997) A Small Ubiquitin-Related Polypeptide Involved in Targeting RanGAP1 to Nuclear Pore Complex Protein RanBP2. Cell, 88, 97-107.
https://doi.org/10.1016/S0092-8674(00)81862-0
|
[8]
|
Matunis, M.J., Coutavas, E. and Blobel, G. (1996) A Novel Ubiquitin-Like Modification Modulates the Partitioning of the Ran-GTPase-Activating Protein RanGAP1 between the Cytosol and the Nuclear Pore Complex. Journal of Cell Biology, 135, 1457-1470. https://doi.org/10.1083/jcb.135.6.1457
|
[9]
|
Saitoh, H. and Hinchey, J. (2000) Functional Heterogeneity of Small Ubiquitin-Related Protein Modifiers SUMO-1 versus SUMO-2/3. Journal of Biological Chemistry, 275, 6252-6258. https://doi.org/10.1074/jbc.275.9.6252
|
[10]
|
Nayak, A. and Müller, S. (2014) SUMO-Specific Proteas-es/Isopeptidases: SENPs and beyond. Genome Biology, 15, Article No. 422. https://doi.org/10.1186/s13059-014-0422-2
|
[11]
|
Desterro, J.M., Rodriguez, M.S., Kemp, G.D. and Hay, R.T. (1999) Identification of the Enzyme Required for Activation of the Small Ubiquitin-Like Protein SUMO-1. Journal of Biological Chemistry, 274, 10618-10624.
https://doi.org/10.1074/jbc.274.15.10618
|
[12]
|
Tatham, M.H., Kim, S., Jaffray, E., Song, J., Chen, Y. and Hay, R.T. (2005) Unique Binding Interactions among Ubc9, SUMO and RanBP2 Reveal a Mechanism for SUMO Paralog Selection. Nature Structural & Molecular Biology, 12, 67-74. https://doi.org/10.1038/nsmb878
|
[13]
|
Ber-nier-Villamor, V., Sampson, D.A., Matunis, M.J. and Lima, C.D. (2002) Structural Basis for E2-Mediated SUMO Con-jugation Revealed by a Complex between Ubiquitin-Conjugating Enzyme Ubc9 and RanGAP1. Cell, 108, 345-356.
https://doi.org/10.1016/S0092-8674(02)00630-X
|
[14]
|
Werner, A., Flotho, A. and Melchior, F. (2012) The RanBP2/RanGAP1*SUMO1/Ubc9 Complex Is a Multisubunit SUMO E3 Ligase. Molecular Cell, 46, 287-298. https://doi.org/10.1016/j.molcel.2012.02.017
|
[15]
|
Jackson, S.P. and Durocher, D. (2013) Regulation of DNA Damage Responses by Ubiquitin and SUMO. Molecular Cell, 49, 795-807. https://doi.org/10.1016/j.molcel.2013.01.017
|
[16]
|
Sarangi, P. and Zhao, X. (2015) SUMO-Mediated Regulation of DNA Damage Repair and Responses. Trends in Biochemical Sciences, 40, 233-242. https://doi.org/10.1016/j.tibs.2015.02.006
|
[17]
|
Moschos, S.J., Jukic, D.M., Athanassiou, C., Bhargava, R., Dacic, S., Wang, X., Kuan, S.F., Fayewicz, S.L., Galambos, C., Acquafondata, M., Dhir, R. and Becker, D. (2010) Expression Analysis of Ubc9, the Single small Ubiquitin-Like Modifier (SUMO) E2 Conjugating Enzyme, in Normal And Malig-nant Tissues. Human Pathology, 41, 1286-1298.
https://doi.org/10.1016/j.humpath.2010.02.007
|
[18]
|
Zhu, S., Sachdeva, M., Wu, F., Lu, Z. and Mo, Y.Y. (2010) Ubc9 Promotes Breast Cell Invasion and Metastasis in a SUMOylation-Independent Manner. Oncogene, 29, 1763-1772. https://doi.org/10.1038/onc.2009.459
|
[19]
|
He, X., Riceberg, J., Pulukuri, S.M., Grossman, S., Shinde, V., Shah, P., Brownell, J.E., Dick, L., Newcomb, J. and Bence, N. (2015) Characterization of the Loss of SUMO Pathway Func-tion on Cancer Cells and Tumor Proliferation. PLoS ONE, 10, e0123882. https://doi.org/10.1371/journal.pone.0123882
|
[20]
|
Kessler, J.D., Kahle, K.T., Sun, T., Meerbrey, K.L., Schlabach, M.R., Schmitt, E.M., Skinner, S.O., Xu, Q., Li, M.Z., Hartman, Z.C., Rao, M., Yu, P., Dominguez-Vidana, R., Liang, A.C., Solimini, N.L., Bernardi, R.J., Yu, B., Hsu, T., Golding, I., Luo, J., Osborne, C.K., Creighton, C.J., Hilsenbeck, S.G., Schiff, R., Shaw, C.A., Elledge, S.J. and Westbrook, T.F. (2012) A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis. Science, 335, 348-353. https://doi.org/10.1126/science.1212728
|
[21]
|
Sabò, A., Doni, M. and Amati, B. (2014) SUMOylation of Myc-Family Proteins. PLoS ONE, 9, e91072.
https://doi.org/10.1371/journal.pone.0091072
|
[22]
|
Evan, G. (2012) Cancer. Taking a Back Door to Target Myc. Science, 335, 293-294.
https://doi.org/10.1126/science.1217819
|
[23]
|
Schimmel, J., Eifler, K., Sigurðsson, J.O., Cuijpers, S.A., Hendriks, I.A., Verlaan-de Vries, M., Kelstrup, C.D., Francavilla, C., Medema, R.H., Olsen, J.V. and Vertegaal, A.C. (2014) Un-covering SUMOylation Dynamicsduring Cell-Cycle Progression Reveals FoxM1 as a Key Mitotic SUMO Target Protein. Molecular Cell, 53, 1053-1066.
https://doi.org/10.1016/j.molcel.2014.02.001
|
[24]
|
Wierstra, I. (2013) FOXM1 (Forkhead Box M1) in Tumorigen-esis: Overexpression in Human Cancer, Implication in Tumorigenesis, Oncogenic Functions, Tumor-Suppressive Prop-erties, and Target of Anticancer Therapy. Advances in Cancer Research, 119, 191-419. https://doi.org/10.1016/B978-0-12-407190-2.00016-2
|
[25]
|
Myatt, S.S., Kongsema, M., Man, C.W., Kelly, D.J., Gomes, A.R., Khongkow, P., Karunarathna, U., Zona, S., Langer, J.K., Dunsby, C.W., Coombes, R.C., French, P.M., Brosens, J.J. and Lam, E.W. (2013) SUMOylation Inhibits FOXM1 Activity and Delays Mitotic Transition. Oncogene, 33, 4316-4329. https://doi.org/10.1038/onc.2013.546
|
[26]
|
Gostissa, M., Hengstermann, A., Fogal, V., Sandy, P., Schwarz, S.E., Scheffner, M. and Del Sal, G. (1999) Activation of p53 by Conjugation to the Ubiquitin-Like Protein SUMO-1. The EMBO Journal, 18, 6462-6471.
|
[27]
|
Muller, S., Berger, M., Lehembre, F., Seeler, J.S., Haupt, Y. and Dejean, A. (2000) c-Jun and p53 Activity Is Modulated by SUMO-1 Modification. Journal of Biological Chemistry, 275, 13321-13329.
https://doi.org/10.1074/jbc.275.18.13321
|
[28]
|
Comerford, K.M., Leonard, M.O., Karhausen, J., Carey, R., Colgan, S.P. and Taylor, C.T. (2003) Small Ubiquitin-Related Modifier-1 Modification Mediates Resolution of CREB-Dependent Responses to Hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 100, 986-991.
https://doi.org/10.1073/pnas.0337412100
|
[29]
|
Yang, Y., Xia, Z., Wang, X., Zhao, X., Sheng, Z., Ye, Y., He, G., Zhou, L., Zhu, H., Xu, N. and Liang, S. (2018) Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel An-ticancer Compounds. Molecular Pharmacology, 94, 885-894.
|
[30]
|
Shanmugam, M.K., Garg, M., Makhija, P., Kumar, A.P., Sharifi-Rad, J., Zam, W. and Bishayee, A. (2021) Ginkgolic Acids Confer Potential Anticancer Effects by Target-ing Pro-Inflammatory and Oncogenic Signaling Molecules. Current Molecular Pharmacology, 14, 806-822. https://doi.org/10.2174/1874467214666210126112413
|
[31]
|
Liu, D., Li, Z., Yang, Z., Ma, J. and Mai, S. (2021) Ginkgoic Acid Impedes Gastric Cancer Cell Proliferation, Migration and EMT through Inhibiting the SUMOylation of IGF-1R. Chemico-Biological Interactions, 337, Article ID: 109394. https://doi.org/10.1016/j.cbi.2021.109394
|
[32]
|
He, X., Riceberg, J., Soucy, T., Koenig, E., Minissale, J., Gallery, M., Bernard, H., Yang, X., Liao, H., Rabino, C., Shah, P., Xega, K., Yan, Z.H., Sintchak, M., Bradley, J., Xu, H., Duffey, M., England, D., Mizutani, H., Hu, Z., Guo, J., Chau, R., Dick, L.R., Brownell, J.E., Newcomb, J., Langston, S., Lightcap, E.S., Bence, N. and Pulukuri, S.M. (2017) Probing the Roles of SUMOylation in Cancer Cell Biology by Us-ing A Selective SAE Inhibitor. Nature Chemical Biology, 13, 1164-1171. https://doi.org/10.1038/nchembio.2463
|
[33]
|
Li, Y.J., Du, L., Wang, J., Vega, R., Lee, T.D., Miao, Y., Al-dana-Masangkay, G., Samuels, E.R., Li, B., Ouyang, S.X., Colayco, S.A., Bobkova, E.V., Divlianska, D.B., Sergienko, E., Chung, T.D.Y., Fakih, M. and Chen, Y. (2019) Allosteric Inhibition of Ubiquitin-Like Modifications by a Class of Inhibitor of SUMO-Activating Enzyme. Cell Chemical Biology, 26, 278-288.E6. https://doi.org/10.1016/j.chembiol.2018.10.026
|
[34]
|
Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., Schneider, L., Muckenhuber, A., Hong, Y., Siegers, G., Nilsson, L., Wirth, M., Dantes, Z., Steiger, K., Schunck, K., Langston, S., Lenhof, H.P., Coluccio, A., Orben, F., Slawska, J., Scherger, A., Saur, D., Müller, S., Rad, R., Weichert, W., Nilsson, J., Reichert, M., Schneider, G. and Keller, U. (2020) SUMO Pathway Inhibition Targets an Aggressive Pancreatic Cancer Subtype. Gut, 69, 1472-1482.
https://doi.org/10.1136/gutjnl-2018-317856
|
[35]
|
Langston, S.P., Grossman, S., England, D., Afroze, R., Bence, N., Bowman, D., Bump, N., Chau, R., Chuang, B.C., Claiborne, C., Cohen, L., Connolly, K., Duffey, M., Durvasula, N., Freeze, S., Gallery, M., Galvin, K., Gaulin, J., Gershman, R., Greenspan, P., Grieves, J., Guo, J., Gulavita, N., Hailu, S., He, X., Hoar, K., Hu, Y., Hu, Z., Ito, M., Kim, M.S., Lane, S.W., Lok, D., Lublinsky, A., Mallender, W., McIntyre, C., Minissale, J., Mizutani, H., Mizutani, M., Molchinova, N., Ono, K., Patil, A., Qian, M., Riceberg, J., Shindi, V., Sintchak, M.D., Song, K., Soucy, T., Wang, Y., Xu, H., Yang, X., Zawadzka, A., Zhang, J. and Pulukuri, S.M. (2021) Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of Cancer. Journal of Medicinal Chemistry, 64, 2501-2520.
https://doi.org/10.1021/acs.jmedchem.0c01491
|
[36]
|
Khattar, M., Grossman, S., Xega, K., et al. (2019) TAK-981: A First in Class SUMO Inhibitor in Phase 1 Trials that Promotes Dendritic Cell Activation, Antigen-Presentation, and T Cell Priming. Cancer Research, 79, Article No. 3252.
https://doi.org/10.1158/1538-7445.AM2019-3252
|
[37]
|
Berger, A., Ghasemi, O., Grossman, S., et al. (2019) Pharmacodynamic Evaluation of the Novel SUMOylation Inhibitor TAK-981 in a Mouse Tumor Model. Cancer Re-search, 79, Article No. 3079.
https://doi.org/10.1158/1538-7445.AM2019-3079
|